NOVOLIN N
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NOVOLIN N (NOVOLIN N).
Insulin analog that lowers blood glucose by promoting cellular uptake of glucose, inhibiting hepatic glucose production, and stimulating lipogenesis and protein synthesis.
| Metabolism | Metabolized by insulin-degrading enzyme (IDE) primarily in the liver and kidneys. |
| Excretion | Renal: 30-80% of dose excreted as unchanged insulin and metabolites. Biliary/fecal: negligible (<1%). |
| Half-life | 10-12 hours for intermediate-acting insulin, with a peak effect at 2-8 hours and duration up to 24 hours. Terminal half-life in subcutaneous depot is 4-6 hours. |
| Protein binding | ~55% bound to albumin and beta-globulins. |
| Volume of Distribution | 0.1-0.2 L/kg, approximating extracellular fluid volume, indicating limited extravascular distribution. |
| Bioavailability | Subcutaneous: 55-80% due to enzymatic degradation at injection site. Intravenous: 100%. |
| Onset of Action | Subcutaneous: 1-2 hours. |
| Duration of Action | Subcutaneous: 18-24 hours, with peak effect at 4-12 hours. Duration is longer with higher doses. |
Subcutaneous injection. Typical starting dose for type 1 diabetes: 0.5-1.0 units/kg/day divided into 2 doses (morning and evening). For type 2 diabetes: 10 units once or twice daily, adjusted based on blood glucose levels.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required for renal impairment; monitor glucose closely. |
| Liver impairment | No specific dose adjustment required for hepatic impairment; monitor glucose closely. |
| Pediatric use | Individualized based on blood glucose goals. Typical starting dose: 0.25-0.5 units/kg/day subcutaneously in 2 divided doses. |
| Geriatric use | Start with lower doses (e.g., 0.25-0.5 units/kg/day) and titrate slowly to avoid hypoglycemia; monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NOVOLIN N (NOVOLIN N).
| Breastfeeding | Insulin is endogenous protein; negligible amounts in breast milk. M/P ratio not applicable. Safe during breastfeeding. |
| Teratogenic Risk | Insulin is not teratogenic. Poor glycemic control increases risks of congenital anomalies (first trimester), macrosomia, neonatal hypoglycemia (third trimester). |
| Fetal Monitoring | Monitor blood glucose, HbA1c, fetal growth ultrasound, amniotic fluid index, fetal heart rate monitoring in third trimester. |
■ FDA Black Box Warning
Never share a NOVOLIN N FlexPen, PenFill cartridge, or vial between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
| Serious Effects |
["Hypersensitivity to insulin NPH or any of its excipients","During episodes of hypoglycemia"]
| Precautions | ["Hypoglycemia: Can occur with insulin therapy; monitor blood glucose levels.","Hypokalemia: May cause hypokalemia; monitor potassium levels in patients at risk.","Fluid retention and heart failure: Can occur, especially when used with thiazolidinediones (TZDs).","Allergic reactions: Local or systemic allergic reactions may occur.","Needle sharing: Risk of blood-borne pathogen transmission; do not share pens or syringes."] |
Loading safety data…
| Fertility Effects | No direct effects on fertility. Glycemic control improves fertility outcomes. |